10
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TQ0078 | CDK-IN-2 | CDK inhibitor II | CDK |
CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM). | |||
T36933 | Cdk2 Inhibitor II | Cdk2 Inhibitor II,CDK2-IN-3 | CDK |
Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM. | |||
T22461 | YKL-5-124 | CDK | |
YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7/Mat1/CycH, CDK2 and CDK9 respectively, displays biochemical and cellular selectivity for CDK7 over CDK12/13... | |||
T8972 | FIT-039 | Others , DNA/RNA Synthesis , CDK , HSV | |
FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1). FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a pr... | |||
T17143 | Toyocamycin | Vengicide | Apoptosis , Others , IRE1 , Antibiotic , Antifungal |
Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM). Toyocamycin induces apoptosis. | |||
T3186 | NU2058 | O6-(Cyclohexylmethyl)guanine,O(6)-Cyclohexylmethylguanine | Topoisomerase , CDK |
NU2058 (O(6)-Cyclohexylmethylguanine) is a guanine-based CDK inhibitor, also inhibits DNA topoisomerase II ATPase activity. | |||
T6187 | TDZD-8 | GSK-3β Inhibitor I,NP 01139 | GSK-3 |
TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | |||
T62235 | CDK-IN-9 | ||
CDK-IN-9 (compound 24) is a potent inhibitor of CDK. CDK-IN-9 is also a molecular gel that induces interaction between CDK12 and DDB1 and is able to act on CDK2/E (IC50: 4 nM). CDK-IN-9 can be used to dephosphorylate ret... | |||
T70988 | Ibulocydine | ||
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomo... | |||
T71549 | RKS-262 | ||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line as... |